Determination of tissue levels of a neuroprotectant drug

The cell permeable JNK inhibitor peptide

Enrico Davoli, Alessandra Sclip, Matteo Cecchi, Sara Cimini, Andrea Carrà, Mario Salmona, Tiziana Borsello

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Cell permeable peptides (CPPs) represent a novel tool for the delivery of bioactive molecules into scarcely accessible organs, such as the brain. CPPs have been successfully used in pre-clinical studies for a variety of diseases, ranging from cancer to neurological disorders. However, the mechanisms by which CPPs cross biological membranes, as well as their pharmacokinetic properties, have been poorly explored due to the lack of specific and sensitive analytical methods. Methods: In this paper we describe a protocol to quantitatively determine the amount of CPPs in in vitro and in vivo experimental models. To this end we selected the peptide D-JNKI1 that was shown to prevent neurodegeneration in both acute and chronic degenerative disorders. This method allows an accurate quantitative analysis of D-JNKI1 in both neuronal lysates and tissue homogenates using mass spectrometry and stable isotope dilution approach. Results: We found that D-JNKI1 crosses cellular membranes with fast kinetics, through an active and passive mechanism. After acute intraperitoneal (ip) administration of D-JNKI1 in mice, the peptide was found in the main organs with particular regard to the liver and kidney. Interestingly, D-JNKI1 crosses the blood brain barrier (BBB) and reaches the brain, where it remains for one week. Discussion: The challenge lies in developing the clinical application of therapeutic cell permeable peptides. Discerning pharmacokinetic properties is a high priority to produce a powerful therapeutic strategy. Overall, our data shed light on the pharmacokinetic properties of D-JNKI1 and supports its powerful neuroprotective effect.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalJournal of Pharmacological and Toxicological Methods
Volume70
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Neuroprotective Agents
Tissue
Peptides
Pharmacokinetics
Pharmaceutical Preparations
Brain
Biological membranes
Membranes
Nervous System Diseases
Blood-Brain Barrier
Isotopes
Liver
Dilution
Mass spectrometry
D-JNKI-1
Mass Spectrometry
Theoretical Models
Kidney
Molecules
Kinetics

Keywords

  • Cell permeable peptide
  • D-JNKI1
  • In vivo sensitive analytic method
  • Mass spectrometry
  • Neurons
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology
  • Medicine(all)

Cite this

Determination of tissue levels of a neuroprotectant drug : The cell permeable JNK inhibitor peptide. / Davoli, Enrico; Sclip, Alessandra; Cecchi, Matteo; Cimini, Sara; Carrà, Andrea; Salmona, Mario; Borsello, Tiziana.

In: Journal of Pharmacological and Toxicological Methods, Vol. 70, No. 1, 2014, p. 55-61.

Research output: Contribution to journalArticle

@article{a1f30676a4c643ac9f7bf2c97cb8c8ae,
title = "Determination of tissue levels of a neuroprotectant drug: The cell permeable JNK inhibitor peptide",
abstract = "Introduction: Cell permeable peptides (CPPs) represent a novel tool for the delivery of bioactive molecules into scarcely accessible organs, such as the brain. CPPs have been successfully used in pre-clinical studies for a variety of diseases, ranging from cancer to neurological disorders. However, the mechanisms by which CPPs cross biological membranes, as well as their pharmacokinetic properties, have been poorly explored due to the lack of specific and sensitive analytical methods. Methods: In this paper we describe a protocol to quantitatively determine the amount of CPPs in in vitro and in vivo experimental models. To this end we selected the peptide D-JNKI1 that was shown to prevent neurodegeneration in both acute and chronic degenerative disorders. This method allows an accurate quantitative analysis of D-JNKI1 in both neuronal lysates and tissue homogenates using mass spectrometry and stable isotope dilution approach. Results: We found that D-JNKI1 crosses cellular membranes with fast kinetics, through an active and passive mechanism. After acute intraperitoneal (ip) administration of D-JNKI1 in mice, the peptide was found in the main organs with particular regard to the liver and kidney. Interestingly, D-JNKI1 crosses the blood brain barrier (BBB) and reaches the brain, where it remains for one week. Discussion: The challenge lies in developing the clinical application of therapeutic cell permeable peptides. Discerning pharmacokinetic properties is a high priority to produce a powerful therapeutic strategy. Overall, our data shed light on the pharmacokinetic properties of D-JNKI1 and supports its powerful neuroprotective effect.",
keywords = "Cell permeable peptide, D-JNKI1, In vivo sensitive analytic method, Mass spectrometry, Neurons, Pharmacokinetics",
author = "Enrico Davoli and Alessandra Sclip and Matteo Cecchi and Sara Cimini and Andrea Carr{\`a} and Mario Salmona and Tiziana Borsello",
year = "2014",
doi = "10.1016/j.vascn.2014.04.001",
language = "English",
volume = "70",
pages = "55--61",
journal = "Journal of Pharmacological and Toxicological Methods",
issn = "1056-8719",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Determination of tissue levels of a neuroprotectant drug

T2 - The cell permeable JNK inhibitor peptide

AU - Davoli, Enrico

AU - Sclip, Alessandra

AU - Cecchi, Matteo

AU - Cimini, Sara

AU - Carrà, Andrea

AU - Salmona, Mario

AU - Borsello, Tiziana

PY - 2014

Y1 - 2014

N2 - Introduction: Cell permeable peptides (CPPs) represent a novel tool for the delivery of bioactive molecules into scarcely accessible organs, such as the brain. CPPs have been successfully used in pre-clinical studies for a variety of diseases, ranging from cancer to neurological disorders. However, the mechanisms by which CPPs cross biological membranes, as well as their pharmacokinetic properties, have been poorly explored due to the lack of specific and sensitive analytical methods. Methods: In this paper we describe a protocol to quantitatively determine the amount of CPPs in in vitro and in vivo experimental models. To this end we selected the peptide D-JNKI1 that was shown to prevent neurodegeneration in both acute and chronic degenerative disorders. This method allows an accurate quantitative analysis of D-JNKI1 in both neuronal lysates and tissue homogenates using mass spectrometry and stable isotope dilution approach. Results: We found that D-JNKI1 crosses cellular membranes with fast kinetics, through an active and passive mechanism. After acute intraperitoneal (ip) administration of D-JNKI1 in mice, the peptide was found in the main organs with particular regard to the liver and kidney. Interestingly, D-JNKI1 crosses the blood brain barrier (BBB) and reaches the brain, where it remains for one week. Discussion: The challenge lies in developing the clinical application of therapeutic cell permeable peptides. Discerning pharmacokinetic properties is a high priority to produce a powerful therapeutic strategy. Overall, our data shed light on the pharmacokinetic properties of D-JNKI1 and supports its powerful neuroprotective effect.

AB - Introduction: Cell permeable peptides (CPPs) represent a novel tool for the delivery of bioactive molecules into scarcely accessible organs, such as the brain. CPPs have been successfully used in pre-clinical studies for a variety of diseases, ranging from cancer to neurological disorders. However, the mechanisms by which CPPs cross biological membranes, as well as their pharmacokinetic properties, have been poorly explored due to the lack of specific and sensitive analytical methods. Methods: In this paper we describe a protocol to quantitatively determine the amount of CPPs in in vitro and in vivo experimental models. To this end we selected the peptide D-JNKI1 that was shown to prevent neurodegeneration in both acute and chronic degenerative disorders. This method allows an accurate quantitative analysis of D-JNKI1 in both neuronal lysates and tissue homogenates using mass spectrometry and stable isotope dilution approach. Results: We found that D-JNKI1 crosses cellular membranes with fast kinetics, through an active and passive mechanism. After acute intraperitoneal (ip) administration of D-JNKI1 in mice, the peptide was found in the main organs with particular regard to the liver and kidney. Interestingly, D-JNKI1 crosses the blood brain barrier (BBB) and reaches the brain, where it remains for one week. Discussion: The challenge lies in developing the clinical application of therapeutic cell permeable peptides. Discerning pharmacokinetic properties is a high priority to produce a powerful therapeutic strategy. Overall, our data shed light on the pharmacokinetic properties of D-JNKI1 and supports its powerful neuroprotective effect.

KW - Cell permeable peptide

KW - D-JNKI1

KW - In vivo sensitive analytic method

KW - Mass spectrometry

KW - Neurons

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84901218334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901218334&partnerID=8YFLogxK

U2 - 10.1016/j.vascn.2014.04.001

DO - 10.1016/j.vascn.2014.04.001

M3 - Article

VL - 70

SP - 55

EP - 61

JO - Journal of Pharmacological and Toxicological Methods

JF - Journal of Pharmacological and Toxicological Methods

SN - 1056-8719

IS - 1

ER -